Quantitative bioanalytical LC-MS/MS services for developing and validating complex methods
LC-MS bioanalysis studies can contribute important data to support preclinical and clinical drug development. Our scientists, located at our GLP Bioanalytical Centre of Excellence, California, USA, have extensive experience in the development, validation and sample analysis of bioanalytical LC-MS assays for parent drug and metabolites in many types of biological matrices for both preclinical and clinical programs.
Our LC-MS teams are specialists in the conduct of US FDA Good Laboratory Practice (GLP) compliant studies. Combined with automated data capture and reporting systems, this has established our laboratory as a leading center of excellence for bioanalysis in North America.
Capabilities include high throughput sample analysis, non-GLP rapid discovery phase bioanalysis, clinical pharmacokinetics (PK), and toxicokinetics (TK) support and specialized bioanalysis for ocular and other tissues. Core expertise includes developing and validating bioanalytical methods that are robust and reproducible, and employing these methods in a high throughput environment to accelerate development times for prescription medicines (Rx drugs) and generics. The laboratory is FDA inspected and GLP-compliant.
LCMS Bioanalysis Services: